Press Releases Keyword Search Year None2022202120202019201820172016201520142013 September 1, 2022 Editas Medicine to Participate in Upcoming Investor Conferences August 3, 2022 Editas Medicine Announces Second Quarter 2022 Results and Business Updates July 27, 2022 Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease July 26, 2022 Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates July 20, 2022 Editas Medicine Reports Inducement Grant to New Chief Medical Officer July 18, 2022 Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer June 7, 2022 Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer June 6, 2022 Editas Medicine Reports Inducement Grants to New Chief Executive Officer May 18, 2022 Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting May 12, 2022 Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
July 27, 2022 Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
July 26, 2022 Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
June 7, 2022 Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
May 18, 2022 Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
May 12, 2022 Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
